Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China · Delayed Price · Currency is CNY 94.42
-1.87 (-1.94%)
At close: Feb 13, 2026
SHA:688266 Revenue
Suzhou Zelgen Biopharmaceuticals had revenue of 217.79M CNY in the quarter ending September 30, 2025, with 51.85% growth. This brings the company's revenue in the last twelve months to 742.28M, up 51.97% year-over-year. In the year 2024, Suzhou Zelgen Biopharmaceuticals had annual revenue of 532.95M with 37.91% growth.
Revenue (ttm)
742.28M
Revenue Growth
+51.97%
P/S Ratio
33.67
Revenue / Employee
815.69K
Employees
910
Market Cap
24.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 532.95M | 146.52M | 37.91% |
| Dec 31, 2023 | 386.44M | 84.13M | 27.83% |
| Dec 31, 2022 | 302.31M | 111.94M | 58.81% |
| Dec 31, 2021 | 190.36M | 162.70M | 588.19% |
| Dec 31, 2020 | 27.66M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DaShenLin Pharmaceutical Group | 26.83B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Yili Chuanning Biotechnology | 4.74B |
| Hualan Biological Engineering | 4.27B |
| Xiamen Amoytop Biotech | 3.70B |
| Sinocelltech Group | 1.89B |
| Inner Mongolia Furui Medical Science | 1.47B |